Menu
Menu
Leaders in translating NET biology into novel therapies
Citryll has leveraged its deep understanding of the pro-inflammatory effect of neutrophil extracellular traps (NETs) to develop therapeutics for the treatment of a broad range of inflammatory diseases.
Next generation therapeutics for treatment of inflammatory diseases
Our lead antibody, CIT-013, is a next generation therapeutic for the treatment of inflammatory diseases. With a unique dual mode of action, CIT-013 has demonstrated a powerful ability to inhibit NETosis and the pathogenic consequences of NETs. It has anti-inflammatory properties across multiple preclinical disease models and inhibits NET release in human volunteers. CIT-013 is currently in Phase I clinical development, and Phase IIa studies in Rheumatoid Arthritis and Hidradenitis Suppurativa are expected to start later this year.
The role of NETosis and NETs in disease
The pathogenic role of NETs in inflammatory diseases has been demonstrated by an increasing body of scientific literature. Citryll has prioritized RA and HS as therapeutic development areas for CIT-013.
Latest News
Citryll and Leading Rheumatology Centres Receive ReumaNederland Grant to Collaborate on NET Research to Advance Novel Treatments for Rheumatoid Arthritis
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces a ground-breaking collaboration with leading rheumatology centres of excellence in the Netherlands funded by ReumaNederland (Dutch Arthritis Society).
Read More
A Year in Review: An Interview with Citryll’s CEO
Celebrating his first year as CEO of Citryll, Eduardo offers a unique perspective on his journey so far. In this exclusive interview, he reflects on the past year's challenges, achievements, and strategic initiatives that have driven the company forward.
Read More
Citryll Completes Patient Dosing In The Repeat Dose Stage Of The Phase 1 Trial
The Phase 1 first-in-human trial is assessing the safety and tolerability of CIT-013. Part D of the Phase 1 trial is investigating the safety and tolerability of repeat dosing in 9 patient volunteers with rheumatoid arthritis (RA) and 3 healthy volunteers.
Read More